Table 2 Characteristics of included studies

Prescribing Domain*

Initiating

   Before drug selection

[16–41]

   After drug selection

[42–53]

Monitoring

[20, 35, 36, 39, 49, 54–71]

Stopping

[39, 42, 61]

Geographic Setting

North America

[16–18, 20, 21, 23, 27–30, 32, 33, 35–45, 47, 49–59, 62, 65–67]

Europe

[19, 22, 24–26, 31, 34, 46, 48, 61, 63, 64, 68–70]

Other

[60, 71]

Target

Physicians

[19–21, 24–27, 29–34, 37, 39, 42, 44–48, 56, 57, 59–69, 71]

Physicians/other health care professionals

[16–18, 22, 23, 28, 35, 36, 38, 40, 41, 43, 49–55, 58, 70]

Initiation of CDSS

System initiated

[16, 18, 20–30, 32, 33, 35–37, 40–53, 58, 60, 62, 63, 66, 67, 70]

User initiated

[17, 31, 34, 54–57, 59, 61, 64, 65, 68, 69, 71]

Mixed/Unclear

[19, 38, 39]

Clinical Setting

Ambulatory

[16–20, 22–28, 31, 32, 35–39, 41–43, 46, 48, 51–54, 58, 59, 61–64, 67–69]

Institutional

[21, 29, 30, 33, 34, 44, 45, 47, 49, 50, 55–57, 65, 66, 71]

Both

[40, 60, 70]

Implementation strategy

CDSS only

[17, 21, 22, 27–29, 34, 36, 37, 40–57, 59–65, 68, 69, 71]

Multi-faceted

[16, 18–20, 23–26, 30–33, 35, 38, 39, 58, 66, 67, 70]

Clinical Area*

Cardiovascular disease

[16–22, 24, 26, 28, 31–33, 35, 37, 38, 46, 62, 67]

Antibiotic therapy

[25, 34, 44, 46, 47, 50, 52, 53, 56]

Vaccinations

[17, 20, 21, 33, 36, 38–41]

Respiratory conditions

[22, 39, 46, 48, 52, 57, 64, 67, 71]

Anticoagulant therapy

[20, 21, 29, 33, 54, 55, 59, 63, 65, 68–70]

Elderly (multiple conditions and drugs)

[42, 43, 45, 49]

Osteoporosis

[23, 33]

Other

[20, 27, 30, 36, 51, 52, 58, 60, 61, 66, 67]